ImmunityBio Return on Equity

ImmunityBio (IBRX) currently reports a ROE of 98.32%. That is above the Healthcare sector average of 29.33%. Use the charts on this page to explore ImmunityBio's ROE history and peer comparisons.

ImmunityBio's ROE of 98.32% is higher than the Healthcare sector average of 29.33%. That is roughly 235.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but ImmunityBio's current 98.32% should be judged against Healthcare norms (sector average: 29.33%) and against IBRX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 98.32%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.33%. From there, open related valuation or income-statement pages for ImmunityBio, and consider following IBRX for alerts when major investors trade the stock.

ImmunityBio is classified in the Healthcare sector. On ROE, it currently shows 98.32% versus a sector average near 29.33%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IBRX with unrelated industries.